Loading…
Major Chinese plasma-products and vaccine maker, producing albumin, immunoglobulin and influenza and other vaccines.
Major Chinese plasma-products and vaccine maker, producing albumin, immunoglobulin and influenza and other vaccines.
Sells albumin and immunoglobulin made from collected plasma, so output depends on how much its state-licensed collection stations can gather, and regulators cap new station licences. Vaccines, led by flu shots, are a second income line with seasonal demand through disease-control centres and hospitals.
In one line: A Chinese CSL/Grifols plus a vaccine business.
Moat: narrow (regulatory licence, scale). One of China's largest plasma-collection networks, capacity that is capped and licensed by the state.
Headquarters: Xinxiang, China · Employees: 4,117
Size Hualan Biological Engineering (002007.SZ) is a China Health Care company (Biotechnology) with a market value of $3.37B, the 769th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.30 on 6 Nov 2026.
Performance Over six months the shares fell 14.7%, against +9.2% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 10.8% over the last twelve months (peer median +20.2%); the operating margin is 16.9% (peer median -75.0%).
Valuation It trades at 25.5× forward earnings against a peer median of 25.4× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points below its cost of capital (8.6% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.80B | CN¥4.58B | CN¥4.36B | CN¥5.32B | CN¥4.50B |
| Revenue growth | — | +5% | -18% | +18% | — |
| Gross profit | CN¥1.98B | CN¥2.51B | CN¥2.56B | CN¥3.59B | CN¥2.84B |
| EBITDA | n/a | CN¥1.41B | CN¥1.45B | CN¥2.08B | CN¥1.51B |
| Net income | CN¥587M | CN¥940M | CN¥1.09B | CN¥1.48B | CN¥1.08B |
| Free cash flow | CN¥804M | CN¥945M | CN¥939M | CN¥680M | CN¥632M |
| Capital expenditure | CN¥181M | CN¥197M | CN¥256M | CN¥753M | CN¥394M |
| Total debt | CN¥628M | CN¥547M | CN¥1.01B | CN¥1.01B | CN¥1.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hualan Biological Engineering 002007.SZ | $3.37B | -15% | -11% | 17% | 25.5× | 16.7% |
| Shanghai RAAS Blood Products 002252.SZ | $4.89B | -11% | -22% | 17% | 13.7× | n/a |
| Beijing Tiantan Biological Products 600161.SS | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% |
| CSL CSL.AX | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% |
| Grifols GRF.MC | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002007.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | +2.9% | 6th lowest of 21 |
| 6-month return | -14.7% | +9.2% | 4th lowest of 21 |
| Distance from 52-week high | -27.6% | -24.0% | 8th lowest of 21 |
| Revenue growth (TTM) | -10.8% | +20.2% | 3rd lowest of 16 |
| Operating margin | 16.9% | -75.0% | 4th highest of 17 |
| Forward P/E | 25.5× | 25.4× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 16.7% | 1.2% | most demanding of 5 |
| Growth delivered (Del g) | -1.8% | +19.9% | lowest of 5 |
| Hurdle (Req g minus delivered) | +18.5 pp | -19.3 pp | most demanding of 5 |
| ROIC minus cost of capital | -2.9 pp | -16.0 pp | 6th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 25.5× | 16.7% | -1.8% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 17.2× | 6.2% | +9.4% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 36.8× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | n/a | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% | +12.5% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 17.1× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 77.2× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 15.7× | -0.8% | +64.6% |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | n/a | n/a | n/a |